Extended treatment with single-agent ibrutinib at the 420 mg dose leads to durable responses in chronic lymphocytic leukemia/small lymphocytic lymphoma

摘要

Purpose:Ibrutinib, a first-in-class, once-daily, oral inhibitor of Bruton’s tyrosine kinase, promotes apoptosis, and inhibits B-cell proliferation, adhesion, and migration. Ibrutinib has demonstrated single-agent efficacy and acceptable tolerability at doses of 420 and 840 mg in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who were treatment naïve (TN) or had relapsed/refractory (R/R) CLL after ≥1 prior therapy in a phase 1b/2 study (PCYC-1102). Subsequently, the ibrutinib 420 mg dose was approved in CLL.